- Home
- ARCT vs CRGX Comparison
ARCT vs CRGX Comparison
Compare ARCT & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- CRGX
- Stock Information
- Founded
- ARCT 2013
- CRGX 2021
- Country
- ARCT United States
- CRGX United States
- Employees
- ARCT N/A
- CRGX N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- CRGX
- Sector
- ARCT Health Care
- CRGX
- Exchange
- ARCT Nasdaq
- CRGX Nasdaq
- Market Cap
- ARCT 602.7M
- CRGX 815.7M
- IPO Year
- ARCT N/A
- CRGX 2023
- Fundamental
- Price
- ARCT $20.60
- CRGX $21.70
- Analyst Decision
- ARCT Strong Buy
- CRGX Strong Buy
- Analyst Count
- ARCT 7
- CRGX 7
- Target Price
- ARCT $65.00
- CRGX $30.33
- AVG Volume (30 Days)
- ARCT 338.5K
- CRGX 416.1K
- Earning Date
- ARCT 11-12-2024
- CRGX 11-21-2024
- Dividend Yield
- ARCT N/A
- CRGX N/A
- EPS Growth
- ARCT N/A
- CRGX N/A
- EPS
- ARCT N/A
- CRGX N/A
- Revenue
- ARCT $163,866,000.00
- CRGX N/A
- Revenue This Year
- ARCT $13.46
- CRGX N/A
- Revenue Next Year
- ARCT $5.17
- CRGX N/A
- P/E Ratio
- ARCT N/A
- CRGX N/A
- Revenue Growth
- ARCT N/A
- CRGX N/A
- 52 Week Low
- ARCT $17.52
- CRGX $13.14
- 52 Week High
- ARCT $45.00
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- ARCT 42.91
- CRGX 58.91
- Support Level
- ARCT $20.00
- CRGX $19.61
- Resistance Level
- ARCT $21.86
- CRGX $19.51
- Average True Range (ATR)
- ARCT 1.49
- CRGX 1.19
- MACD
- ARCT -0.35
- CRGX 0.36
- Stochastic Oscillator
- ARCT 18.04
- CRGX 73.67
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.